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ABSTRACT
Simple water soluble lanthanum and europium complexes are effective at
detecting neutral sugars as well as glyco- and phospholipids. In solutions at
physiologically relevant pH the fluorescent lanthanum complex binds neutral sugars with
apparent binding constants comparable to those of arylboronic acids. Interference from
commonly occurring anions is minimal. The europium complex detects sialic acidcontaining gangliosides at pH 7.0 over an asialoganglioside. This selectivity is attributed,
in large part, to the cooperative complexation of the oligosaccharide and sialic acid
residues to the metal center, based on analogous prior studies. In MeOH,
lysophosphatidic acid (LPA), a biomarker for several pathological conditions including
ovarian cancer, is selectively detected by the europium complex. LPA is also detected via
a fluorescence increase in human plasma samples. The 2-sn-OH moiety of LPA plays a
key role in promoting binding to the metal center. Other molecules found in common
brain ganglioside and phospholipid extracts do not interfere in the ganglioside or LPA
fluorescence assays.
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CHAPTER 1
INTRODUCTION
1.1. Lanthanide Complexes in Supramolecular Chemistry
Lanthanides complexes have gained significant attention due to their unique
chemical and physical properties.1.1 The prime interest towards such complexes originate
from so-called “ligand-field extension”. Unlike transition metal complexes wherein the
ligand complexation is of both covalent and ionic character, lanthanide coordination is
largely ionic. Consequently, lanthanides, even if in electrically neutral form, can bind to
additional neutral or ionic ligands whereby they can achieve coordination numbers up to
12.

N

(H3C)3C
O

N

Eu
O
N

(H3C)3C
3

Figure 1.1. Europium tris(2,2,6,6-tetramethyl-3,5-heptadionate) and highly coordinated
complexation with terpryridine.
Consequently, the use of such complexes have been widely reported in: (a) light
converters, (b) Nuclear Magnetic Resonance and (c) catalysts in both chemical and
biological systems. The field of application of lanthanides have also strecthed out to
molecular recognition, especially recognition of biomolecules such as amino acids,
nucleic acids, charged carbohydrates.
Although such biomolecules have been known to participate to several
physiological conditions, their in vivo functions are not fully understood. Hence, their
1

quantification in physiological states by simple spectroscopic methods are of paramount
importance. Hence, we have turned our attention to the design and synthesis of
lanthanide-based chemosensors to quantify neutral carbohydrates and certain cancer
biomarkers such as lysophosphatidic acid (LPA) and gangliosides.
1.2. Selective Detection of Lysophosphatidic Acid for Early Diagnosis of Ovarian
Cancer
Ovarian cancer is a devastating health problem. Nearly 10 million women in the
US are at high risk for ovarian cancer. There are 26,000 new US cases per year.1.2 The
lack of effective methods for the early diagnosis of ovarian cancer is a serious health
problem. Ovarian cancer is a deadly gynecological disease.
Survival rates increase dramatically with early diagnosis.

Ovarian cancer is

extremely difficult to detect early enough to allow for effective treatment. To quote from
a recent assessment: "Ovarian cancer is an insidious disease that kills more than 15,000
Americans each year.1.3 The lethality of this disease stems from our inability to diagnose
it easily and early; this is because its symptoms — such as nausea, loss of appetite and
abdominal discomfort — are common to many disorders. Consequently, most women
are diagnosed with ovarian cancer in the late stage of the disease, for which the five-year
survival rate is less than 30%. Yet, survival rates soar to over 90% if the disease is
discovered when cancer is still localized to the ovaries."1.2,1.3 There are significant
barriers to the diagnosis of early stage ovarian cancer.
Current methods used to identify ovarian cancer include transvaginal ultrasound,
laparoscopy, or positive emission tomography. While transvaginal sonography shows
promise for early detection, it is too expensive to be widely used for routine screening.1.4

2

The correlation of altered levels of serum biomarkers to ovarian cancer have been the
subject of many studies. The protein CA-125 is currently the main biomarker of choice.
However, other physiological conditions also promote increased CA-125 levels. CA-125
is less specific in premenopausal women. The well-known low accuracy of CA-125,
even in combination with other methods, has led to intensive efforts to find better
biomarkers. For instance, detailed computer analyses of the mass spectrometric data
obtained from ovarian cancer and non-cancer subjects afforded nearly 100% accuracy of
detection.1.5 This exciting report indicates that the early detection of ovarian cancer may
be possible; however, this method is expensive, not point-of-care, and different analyses
of the same data suggest different biomarker molecules. For a detailed discussion of the
drawbacks and complexity of this method, see references 1.2 and 1.6.
It is generally agreed that LPA monitoring is a useful biomarker for early
detection.

LPA (oleoyl-L-α-lysophosphatidic acid) is a bioactive phospholipid with

mitogenic and growth factor-like activities, an “oncolipid,” which stimulates the
proliferation of cancer cells, and, as concluded in a recent review, "ovarian cancer
appears to be driven through the production and action of LPA."1.8 There is general
agreement in the biomedical literature that monitoring plasma LPA levels is potentially a
highly promising way to detect ovarian cancer in its early stages.1.2,1.7,1.8 Findings in this
area came from the lab of Xu et al., who found that plasma LPA levels afford a more
sensitive diagnostic compared to CA-125.
LPA’s use as a biomarker is limited due to current problems with its monitoring.
Large-scale population studies with the capability of yielding more-precise estimates of
the sensitivity and specificity of LPA, both alone and in combination with other markers,
for both screening and detection of recurrence, are necessary, as stated in a recent paper
3

of Sutphen et al.1.7

Currently, there are no methods that allow for very efficient

monitoring of elevated LPA. For example, using analytical HPLC, researchers could not
separate some LPAs from lysophosphatidyl inositols (LPIs). In a recent article, scientists
from Sloan-Kettering state that LPA is a potentially useful ovarian cancer biomarker;
“however, the current method of measuring LPA, which involves lipid extraction
followed by gas chromatography, may limit its utility.”1.9
Additionally, controversy regarding the reliability of LPA as an early-stage
ovarian cancer marker exists due to problems with LPA isolation and handling:
"…differences in the results from the groups likely arise from challenges in the collection
and handling of plasma to prevent post collection production, metabolism or loss of LPA.
A very significant complication is that during sample incubation prior to many analyses,
significant enzyme generated elevation in serum LPA levels occurs (i.e., non-tumorrelated), greatly hindering diagnosis of ovarian cancer."1.8
A summary of specific current problems with LPA detection:
(a) It is difficult to extract and quantify LPAs in the presence of other lipids [e.g.,
phosphatidylcholine, (PC) and sphingomyelin (SM)], which are present at much higher
concentrations (in addition to LPI).1.10
(b) Routine laboratory analysis demands minimum sample preparation. The LPA
extraction process is complex and time-consuming, due in part to the structure of the
LPAs. Ideally, direct LPA detection from blood without any sample preparation is
required.1.7,1.10

4

(c) Studies have revealed that plasma LPA levels can be misleading. If the sample is
incubated, LPA levels increase via biosynthesis via lysophospholipase activity, rather
than originating from tumors! Hence, LPA detection in plasma will be misleading as
long as non-tumorogenic biosynthesis is not blocked.
O
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H HN

C15H31
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L-α-phosphatidylinositol (PI)

Figure 1.2. The structures of LPA and other phospholipids.

To date, several methodologies have been used to address the selective and
sensitive detection of LPA. These include HPLC1.10, tandem mass spectroscopy1.6, thinlayer chromatography (TLC)1.11, capillary electrophoresis with indirect ultraviolet
detection,1.12 radio-enzymatic assays1.13 and voltage clamped Xenopus oocytes.1.14 These
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approaches involve expensive, sophisticated devices and complicated procedures
unsuited for point-of care applications; for example,
(i)

GC analysis necessitates esterification of the lipids prior to analysis. Although

techniques such as HPLC or GC and mass spectroscopy may achieve selectivity and
sensitivity, simpler methods allowing routine diagnosis of LPA are more desirable.
(ii)

The problems related to LPA separation via 2D-TLC are complicated by the

fact that the same LPA salts with differing counter ions (e.g., calcium and sodium)
exhibit different mobilities, regardless of the nature of stationary phase material.
(iii)

Colorimetric and fluorometric techniques are generally preferred, due to their

simplicity. The only colorimetric LPA detection reported uses an enzymatic cycling
method.1.15 In general, enzymes have relatively limited shelf life and stability and are
relatively expensive, compared to synthetic materials. In the particular case of this
aforementioned of the enzyme cycling method, indirect detection (peroxide) is used to
determine LPA levels. However, this methodology has to date never been cited since its
publication (2003) in the context of its embodying a feasible method for LPA detection.
(iv)

Direct chromatographic detection with absorption spectroscopy is feasible but

at wavelengths below 215 nm. Unfortunately, this region is where solvent and solvent
trace impurity absorption becomes substantial.1.10
1.3. Non-hydrolytic Detection of Gangliosides
Glycosphingolipids (GSLs) are complex lipid molecules that are components of
eukaryotic cell membranes.1.16 The structures of some sphingolipids are shown in Figure
1.1. Typically, they consist of at least one monosaccharide that is glycosidically linked to
hydrophobic lipid residues such as sphingosine or ceramide. The nature of these lipids
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depends on the cell type; sphingosine is mostly found in mammalian cells whereas
phytosphingosine is encountered in yeast and plant cells. Modifications of the lipid
backbone that range from phosphorylation to gluco- and galactosylation generate large
structural diversity.

Indeed, more than 300 biomolecules are currently known as

glycosphingolipids. They are an integral part of the eukaryotic cell membrane with their
sugar residues residing on the outer layer of the membrane. The orientation of the sugar
residues renders these glycolipids critical in numerous intercellular processes including
cellular protection against both mechanical and chemical damage, proliferation,
differentiation, cell-cell recognition and cell development. They moreover function as
receptors for lectins, selectins, toxins and viruses. However, their in vivo functions are
not fully understood.1.16
Their metabolism is linked to the synthesis of several biomolecules.
Glycosphingolipids are synthesized in the endoplasmic reticulum and Golgi apparatus
while being catabolized in lysosomes. The condensation of palmitoyl-CoA and serine is
a common step in all glycosphingolipid syntheses which initiate the individual
biosynthetic pathways. Whereas the anabolism of glycosphingolipids allows access to
several metabolic products (for instance, sphingomyelin can be synthesized from
ceramide simply via the addition of a phosphorylcholine residue), their catabolism is
mostly essential for biomolecular recycling purposes. This recycling route commences
with the import of macromolecules into lysosomes by several mechanisms such as
endocytosis, pinocytosis, phagocytosis and autophagocytosis. Therein, macromolecules
are cleaved by acidic hydrolytic enzymes and some accessory proteins that are utilized
for sequential degradation. Thereafter, the hydrolytic products are carried back to the
cytoplasm for reutilization. This process is also essential since it constitutes the first step
7

of the synthesis of some key molecules such as ceramide which is vital in signal
transduction.1.16
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O
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Figure 1.3. The structures of selected sphingolipids.

Defects in GSL metabolism can potentially have severe consequences that result
in metabolic disorders. Interestingly, these disorders are related to their catabolism, not
their biosynthesis.

There is no disease known to originate from defects in

glycosphingolipid synthesis.

Conversely, failure in their catabolism results in their

extensive accumulation in tissues, which leads to physiological conditions also known as
lysosomal storage diseases. To date, more than 40 different types of lysosomal storage
diseases are known.

Although the frequency of each lysosomal storage disease is

relatively rare, their cumulative effect can be significant.1.16
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The deficiency of the corresponding hydrolytic enzymes in lysosomes is the
origin of the storage diseases. The reason for this deficiency is defects in genes that
encode the enzymes. Studies toward the underlying mechanism of these defects have
revealed that the expressed enzymes possess relatively low or no activity. Accordingly, it
was found that mutations in genes cause alterations in nucleotide bases that are in close
proximity to the active site. These mutations include base substitution, insertion or
deletion and partial gene deletion. Relatively mild mutations, on the other hand, may
alter the stability of both mRNA and the enzymes.
determined by the extent of the mutations.

The severity of the disease is

Although regarded as indirect effects,

mechanisms such as deficiency in lysosomal enzyme transport or localization are also
known. The lack of enzymes and the associated lysosomal storage diseases are
summarized in Table 1.1.1.16-1.18
Gangliosides

(Figures

1.2

and

1.3)

are

the

sialic

acid-containing

glycosphingolipids. They exhibit the greatest structural variation and complexity of the
GSLs. Gangliosides are characterized by a high amount of stearic acid (C18, about 80%)
in their hydrophobic region, as well as C16, C20 and C22. Changing the fatty acid
component to α-linoleic acid alters biological activity dramatically in vitro. However, it is
the carbohydrate moiety that is of primary importance in determining distinctive
ganglioside properties. In any given cell type, the number of different gangliosides may
be relatively small, but their nature and compositions may be characteristic and highly
relevant to the functioning of the cell.1.16-1.18
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Table 1.1. Sphingolipid, glycosphingolipid and lysosomal storage diseases (adapted from
reference 1.16d).
Disease
Enzymatic defect
GSL storage material
β-glucosidase, saposin
Glucosylceramide,
Gaucher
C activator
GM1, GM2, GM3, GD3,
Glucosylsphingosine
Sphingolipid activator
Glycolipids
Sphingolipid
protein
activator deficiency
GM1 gangliosidosis
GM1, GM2, GM3, GD1A
GM1 gangliosidosis
β-Hexosaminidase A
GM2, other glycolipids
Tay Sachs
β-Hexosaminidase A
GM2, other glycolipids
Sandhoff
and B
GM2 activator protein
GM2, other glycolipids
GM2 activator
deficiency
β-Galactosidase
Galactosylceramide
Krabbe
α-Galactosidase A
Globotriaosylceramide
Fabry
and blood group B substances
Arylsulfatase A, saposin
Sulphated glycoproteins
Metachromatic
B activator
and glycolipids, and GM2
leukodystrophy
Ceramidase
Ceramide, GM3
Farber
Sphingomyelinase
Sphingomyelin, GM2, GM3
Niemann-Pick A & B
α-Fucosidase
Fucosides and glycolipids
Fucosidosis
Oligosaccharides,
GlcNac transferase
mucopolysaccharides,
Mucolipidosis II & III
lipids, GM1
Various enzymes
GM2 and GM3
Mucopolysacharidosis
I, II, III, VII
Α-mannosidase
GM2, GM3
Alpha mannosidosis
Protective protein
GM1, GM2, GM3
Galactosialidosis
cathepsin A

iv
OH

iii

OH

OH OH

O

ii

O

HO
OH

O
O
H3C -

O

NH
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O
O
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HO
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O
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Figure 1.4. Structures and symbolism for gangliosides and their asialo derivatives,
glucosylceramide, and N-acetyl-α-neuraminic acid: (GlcCer): R, i; (GalCer): R, ii;
(LacCer): R, i, ii; (GA2): R, i, ii, iii; (GA1): R, i, ii, iii, iv; (GM4): R, ii, A; (GM3): R, i,
ii, A; (GM2): R, i, ii, iii, A; (GMl): R, i, ii, iii, iv, A; (NeuAc): A (adapted from ref. 1.19).
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As the brain develops, the content of gangliosides and the degree of sialylation
increases. Numerous biological properties of gangliosides related to cellular and
molecular recognition have been attributed to the sialic acid residues. They are involved
in the binding and the transport of positively charged molecules as well as the attraction
and repulsion of the cells. Due to their terminal position on glycolipids, sialic acids
mostly function as receptors for a large variety of molecules such as hormones, toxins,
viruses, cells and bacteria. In addition, they behave as ligands for lectins and selectins
during a number of cell-cell and cell-matrix processes. Interestingly, they are known to
shield the recognition sites whereby the activation of the immune system is inhibited.
Accordingly, oversialylation of the cell surface results in the protection of malignant
cells. For these reasons, it is clear that sialic acids play roles in tumor biology. In fact,
imbalances in sialic acid levels can have clinical manifestations such as alterations in cell
adhesion, a condition implicated in some cancers, and graft rejection. An increase in the
levels of both soluble and cellular sialic acid can thus be a marker for cancer.1.17
However, since the levels of sialic acids can also be altered by non-pathological factors
(e.g., smoking, pregnancy and age), altered levels do not solely indicate the presence of
cancer and must be viewed in conjunction with other markers for diagnostic purposes.1.2
N-Acetylneuraminic acid (Neu5Ac) is the most abundant form in humans. As a
part of glycosphingolipids (i.e., the gangliosides) or glycoproteins, they typically occupy
the terminal position of the glycan chain. An interesting aspect of sialic acid chemistry is
that the anomeric configuration is determined by whether sialic acid is in a free or
conjugated form. In solution, the anormeric equilibrium between the α- and β- favors the
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Scheme. 1.1. Pathways for the biosynthesis of the common series of gangliosides
involving sequential activities of sialyltransferases and glycosyltransferases.

latter. However, sialic acids, when conjugated to biomolecules, are predominantly in the
α-anomer form.1.17
•

Major Biochemical Properties of Gangliosides. Gangliosides are ligands for

myelin stability and aid in nerve regeneration by binding a myelin-associated
glycoprotein. They can act as cell-type specific antigens controlling cell growth and
differentiation and intercellular interactions. They play key roles in the immune systems
and serve as biomarkers of cancerous tissue.

They regulate cell signaling, serving as

receptors for interferon, epidermal growth factor, nerve growth factor and insulin.
Gangliosides bind to bacterial toxins and mediate interactions between microbes and host
cells during infections. Genetic defects in catabolism lead to ganglioside accumulation.
In generalized gangliosidosis, excess GM1 in the nervous system results in mental
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retardation and liver enlargement. In Tay-Sachs syndrome, GM2 accumulation in the
brain leads to mental retardation and blindness.1.16-1.18
Table 1.2. Selected examples of studies using total ganglioside determination for
research on various cancers.
Disease
Levels
Matrix
Reference
15.6 – 58.6 mg/dL
Serum
1.4
Colorectal Cancer
16.6 – 34.6 mg/dL
Serum
1.5
Pancreatic Adenocarcinoma
2.7 – 4.8 mg/mL/105
Tumor Cells
1.6
cells/24 h
Advanced Ovarian Cancer
14 – 40 mg/mL
Peritoneal Fluid
18 – 57 mg/mL

•

Plasma

The Significance of Total Ganglioside Determination for Modern Biomedical

Research. Gangliosides account for 6 % of brain tissue. The main gangliosides found in
the human brain are GM1, GD1a, GD1b and GT1. GM3 is mainly localized in extraneural
tissues. The overall composition of the gangliosides can be influenced by environmental
factors as well as by nerve stimulation or drug administration. The determination of total
ganglioside content is highly useful in studying storage diseases (Table 1.1) and in the
investigation of specific cancers (Table 1.2).1.20-1.24 Recent investigations show that
serum total ganglioside (STG) levels have shown promise as a potential tool for assessing
the response to immunotherapy in melanoma patients.1.23

Additionally, in a recent

example, total ganglioside content was recently shown to increase by 20-fold in studies
involving the links between lipid metabolism and Alzheimer’s disease.1.24a
This represents a relatively small subset of many recent investigations.
Ganglioside detection is a major challenge. Because biological media contain a high
content of other lipids, extensive purification of gangliosides by methods such as
reversed-phase chromatography and DEAE-Sephadex columns are often required prior to
13

analysis.

Table 1.3 summarizes the most commonly used current methods for

ganglioside detection.

Simple and rapid, reliable and user-friendly techniques are

needed:
According to Tsui et al.,1.24b “conventional strategies for profiling gangliosides
suffer from poor reproducibility, low sensitivity, and low throughput capacity. Prior
separation of gangliosides by thin-layer chromatography and/or high-performance liquid
chromatography not only was tedious and laborious but also could introduce uneven
losses of molecular species.” These researchers prove that it is necessary to separate
phospholipids from gangliosides to obtain satisfactory MS data. In fact the method
ultimately used required partitioning of gangliosides into an aqueous phase to obtain
enrichment. Aqueous phase partitioning requires purification via gel filtration to remove
low molecular weight contaminants such as salts and peptides. Percent recovery in the
aqueous phase was not described; however, others have described moderate sample
losses during sample handling prior to analysis.
In another recent representative example, Sato et al.1.24a used the following
procedure prior to analyzing total ganglioside content in embryonal carcinoma cells:
lipids were extracted from cells successively in CHCl3/MeOH, total lipid extract was next
“further purified”, then separated by TLC using CHCl3/MeOH/0.2 % CaCl2 (55:45:10),
detected with orcinol sulfuric acid reagent and quantified with a dual-wavelength flying
spot scanner in reflectance mode at 500 nm. This method also partitions and detects
other “acidic glycolipids”. Therein, potential interferences/co-elution was not described.
More importantly, the orcinol reagent is non-selective and reacts with reducing sugars.
Sample pre-treatment procedures may be written in a somewhat simplified
manner in experimental sections.

For example, in a recent volume of Methods in
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Enzymology (vide infra), an initial “total lipid extraction” step can entail lyophilization,
pulverization, re-suspension in solvent, sonication, 18 h re-extraction, centrifugation, reextraction, clarification, extract combination, concentration, centrifugation, partitioning
and drying. This is all done prior to the partitioning of gangliosides from other lipids.
The ensuing partitioning step involves addition of mixed alcohol solvents to the extract,
vortexing, sonication, addition of saline solution, alternating vortexing and sonication,
centrifugation, removal of the organic solvent and repartioning the aqueous layer.
Alternating vortexing and sonication is again repeated, and organic solvent is removed
followed by lyophilization. The sample is then loaded onto a Sephadex G-50 column
using very precise specifications. Recoveries from the individual steps are reported to be
93 % or higher.
It is, in other words, relatively tedious to purify the gangliosides and prepare them
for analysis. We thus propose an extensive study aimed at developing highly selective
receptors. Our goal is to provide simple and enabling new methods for ganglioside
research and ultimately for the early and efficient screening of ganglioside-related
diseases. We envision that the detailed spectroscopic work planned will guide the near
future development of reagents not just for detecting gangliosides, but also neutral
glycolipids. For example, future targets would include the smaller glycosphingolipids
glucosylceramide and lactosylceramide, for which there aren't good reagents available.
Table 1.3. Major current techniques used for ganglioside detection and their associated
challenges (summarized from the introduction in reference 1.9b).
Main Challenge
Technique
Antibodies
Cross-react with multiple gangliosides and/or glycoprotein species
with similar carbohydrate epitopes.
TLC
Low resolution does not adequately resolve heterogeneity of
gangliosides
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Table 1.3. Continued
HPLC
MS/TLC or
MS/HPLC
Tandem MS/MS

Laborious purification, and requiring derivatization with
chromogens/fluorogens
Tedious purifications/derivatizations
Ganglioside ionization is significantly suppressed by samples
containing other biomolecules such as phospholipids
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CHAPTER 2
LANTHANIDE COMPLEXES AS FLUORESCENT INDICATORS
FOR NEUTRAL SUGARS AND CANCER BIOMARKERS*

2.1. Introduction
Nature uses tools such as lectins for the molecular recognition of saccharides. An
important mode of lectin binding involves the coordination of a carbohydrate ligand to a
metal center. C-type lectins recognize saccharides in a calcium-dependent manner.2.1 The
similar properties of lanthanides and calcium render trivalent lanthanides ions useful
substitutes for Ca2+ in studying proteins.2.2 Herein, we describe the utility of water
soluble salophene2.3-lanthanide complexes (Figure 2.1) towards addressing three current
challenges: (i) the detection of neutral carbohydrates at physiologically-relevant pH, (ii)
the selective detection of gangliosides and (iii) the selective detection of lysophosphatidic
acid (LPA).

OCH3
HO

O

O

N

O
Ln

HO

O

O

N

O
OCH3

2.1 Ln = La3+
2.2 Ln = Eu3+

Figure 2.1. Salophene-lanthanide complexes.
*Reprinted in part with permission from Proceedings of the National Academy of
Sciences of the United States of America, 2006, Volume 103, pages 9756-9760; Onur
Alpturk, Oleksandr Rusin, Sayo O. Fakayode, Weihua Wang, Joege O. Escobedo, Isiah
M. Warner, Williams E. Crowe, Vladimir Kral, Jeff M. Pruet, and Robert M. Strongin,
Lanthanide Complexes as Fluorescent Indicators for Neutral Sugars and Cancer
Biomarkers. Copyright 2006 National Academy of Sciences, U.S.A.
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2.2 Results and Discussion
2.2.1. Detection of Neutral Sugars at Physiological pH.
A main problem in the detection of neutral sugars with artificial receptors is
competitive binding by bulk water. Elevated solution pH is therefore typically required to
attain a useful degree of coordination and signal transduction in the most innovative new
metal-based detection methods.2.4 There is an unmet demand for biomimetic sugar
sensing agents that function in neutral buffer solution.2.4 Since La3+ and Ca2+ exhibit
relatively strong affinity for saccharides as compared to most other metal ions,2.5 we
hypothesize that 2.1 may be useful for detecting sugars in neutral aqueous media.
Interestingly, lanthanides can extend their ligand coordination number by the addition of
either neutral or charged ligands through ligand-sphere extension, leading to highly
coordinated complexes.1.1
Addition of saccharides (1.1 × 10-3 M) to a solution of 2.1 (5.53 × 10-6 M, 0.1 M

Fluorescence Intensity

HEPES buffer, pH 7.0) promote readily-monitored increases in emission (Figure 2.2).2.6
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Figure 2.2. Fluorescence changes observed upon titration of 2.1 with D-glucose in 0.1M
HEPES buffer, pH 7.0. The concentration of 2.1 is 6 × 10-6 M. The concentration of
glucose is increased from 0 to 6 × 10-4 M. Excitation is at 360 nm, emission is monitored
at 400 nm.

20

Lanthanide coordination to salens whereby the ligand conformation is brought
into a more rigid cyclic structure, increases ligand-centered fluorescence emission.2.6
Ternary complex formation upon saccharide addition apparently enhances this latter
effect. In the 1H-NMR of a solution of 2.1 and D-glucose in D2O, the imine protons of
2.1 exhibit a modest up-field shift, in keeping with analogous salophene-metal complexes
upon binding analytes2.3 (Figure 2.3).

Figure 2.3. 1H-NMR study of glucose titrated with 2.1: (a) 1.8 mg of glucose in 0.75 ml
of D2O; (b) after addition of 0.2 equiv 2.1; (c) after the addition of 0.4 equiv 1; (d) after
addition of 0.6 equiv 2.1 (1.5 mg of 2.1 in 0.1 ml of D2O in each addition). The imine
protons of 2.1 exhibits a modest up-field shift (from 9.84 ppm to 9.79 ppm) in keeping
with analogous salophene-metal complexes upon binding analytes (see reference 2.3 for
analogous responses in the NMR of other salophenes upon tertiary complex formation).
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Figure 2.4. (Top) Job’s plot of 2.1 and D-glucose in 0.1M HEPES buffer pH 7.0 and
(Bottom) Job’s plot of 2.1 and maltotriose in 0.1M HEPES buffer pH 7.0 both of which
indicate a 1:1 stoichiometry.
The continuous variation indicates a 1:1 stoichiometry between glucose, maltose,
maltotriose and 2.1 (Figure 2.4). Glucose, maltose and maltotriose exhibit binding
constants of 500, 1666 and 2500 M-1 respectively. These values compare very favorably
to those of sugar-boronate complexes.2.7 This is significant since boronic acid-containing
fluorophores are currently reagents of choice for sugar detection in aqueous and mixedaqueous media. The emission enhancements shown herein in the presence of neutral
sugars range from ca. 25% – 60% (Figure 2.5).
Common anions (citrate, phosphate and pyrophosphate) studied under these
conditions promote relatively weaker emission responses. Additionally, bovine serum
albumin-containing solutions exhibit increased fluorescence only when glucose is
present. The concentration of glucose in plasma is typically ca. 10-3. The next most
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abundant monosaccharides are galactose and fructose, present at concentrations of 2
orders of magnitude less than that of glucose.

Investigations towards minimizing

potential interferences as well as improving selectivity for specific neutral sugars are in
progress.
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Figure 2.5. Relative fluorescence emission (400 nm) changes observed in solutions of
2.1 (5.53 × 10-6 M) in the presence of mono-, oligosaccharides, anions (1.1 × 10-3 M),
BSA (1 mg/mL) and a mixture of BSA and glucose (1 mg/mL and 1.1 × 10-3 M,
respectively) in HEPES buffer solution (pH 7.0). The standard deviation (n=3 for each
analyte) of the relative fluorescence intensity ranges from 0.01-0.027.
2.2.2. The Selective Detection of Gangliosides under Neutral Conditions
It is well-known that an increase or decrease in total sialic acid levels (conjugated
plus freely circulating) in biological fluids can indicate the occurrence of certain cancers.
The acid-catalyzed liberation of bound sialic acid residues from gangliosides for assay
typically results in destruction of the analyte.2.8 In the case of enzymatic hydrolysis
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incomplete sialic acid liberation is a problem.2.9 Effective sensing agents for sialic acidcontaining gangliosides (Figure 2.6) are needed.
OH

NHAc

HO

CH2OH
O

O

O

O

O

HO CH2OH

O
asialoganglioside (asialo-GM1), R = H

O

O

HO

HO CH2OH

OH

HO
O

CH2OH
H

R

H

HO

NH

OH
monosialoganglioside (GM1), R =

O

NHAc

O

14

OH

Na+-OOC
HO

16

CH2OH

Figure 2.6. The structures of asialo-GM1 and GM1.
Selectivity towards various anionic substrates can be tuned via the appropriate
choice of lanthanide metal.2.10 Importantly, Sillerud et al. have provided precedent for
favorable cooperative binding interactions of the oligosaccharide and sialic acid moieties
of micellar gangliosides with Eu3+.2.11 For example, the higher affinity of Eu3+ to GM1 as
compared to sialic acid was attributed not only to an electrostatic interaction with the
GM1 sialic acid carboxylate but also to secondary interactions with the proximal
oligosaccharide hydroxyls. This results in a coordination shell (Figure 2.7).
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Figure 2.7. Left: Coordination of GM1 to Eu3+. Right: Free sialic acid
We thus hypothesize that 2.2 may afford enhanced signaling in the presence of
charged gangliosides as compared to neutral sugars and sialic acid. Compound 2.2
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promotes the detection of sialic acid-containing gangliosides selectively compared to
asialo-GM1 (Figure 2.8 and Figure 2.9). In contrast, 2.1 affords greater fluorescence
enhancement than 2.2 in the presence of neutral asialo-GM1 (Figure 2.10).
The smaller the ionic radius of a lanthanide is, the more significant are the
intramolecular interactions between its ligands. The salophene ligands of 2.1 and 2.2
contain both polar and apolar moieties. The combination of these latter structural features
along with the smaller ionic radius of Eu3+ compared to La3+, apparently renders 2.2 a
better substrate for detecting anionic gangliosides compared to 2.1.
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Figure 2.8. Fluorescence intensity change of solutions of 2.2 (5.53 × 10-6 M) in response
to added gangliosides (0.5 mg/mL, ca. 10-4 M each) and sialic acid (1 × 10-3 M) in 0.1 M
HEPES buffer solution (pH 7.0). Excitation 360 nm, emission 400 nm.
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Figure 2.9. Relative fluorescence intensity changes of solutions of 2.2 (5.53 × 10-6 M) in
HEPES buffer pH 7.0 in the presence of various gangliosides, phospholipids and other
charged and neutral analytes. Ganglioside concentration = 0.5 mg/mL, ca. 10-4 M each.
Concentration of other analytes = 1.1 × 10-3 M. The standard deviation (n=3) of the
relative fluorescence intensity for each analyte ranges from 0.01-0.11. Proteins such as
myelin and BSA were studied at 1 mg/mL concentrations. Asialoganglioside GM1 =
Asialo-GM1; monosialoganglioside GM1 = GM1; disialogangliosides = GD1a and GD1b;
L-α-phosphatidyl inositol = PI; L-α-phosphatidyl ethanolamine = PE;
L-α-phosphatidyl serine = PS; CMP-NANA=Cytidine-5'-mono phospho-Nacetylneuraminic acid).
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Figure 2.10. Relative fluorescence intensity spectra of compounds 2.1 and 2.2 in the
presence of gangliosides in 0.1M HEPES buffer pH 7.0. Gangliosides GM1 and GD1a
contain sialic acid moiety; Ganglioside asialo-GM1 does not contain the sialic acid
moiety.
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Figure 2.11. 1H-NMR study of a titration of sialic acid with 2.2: (a) 0.73 mg of sialic
acid in 0.75 ml of D2O; (b) after addition of 0.2 equiv 2.2; (c) after the addition of 0.4
equiv 2.2; (d) after the addition of 0.6 equiv 2.2 (0.35 mg of 2.2 in 0.1 ml of D2O in each
addition). When sialic acid is titrated with 2.2, the NMR signals corresponding to the
protons on the glycerol side chain and pyranose ring undergo substantial peakbroadening. The 3-Hax proton, on the same side of the pyranose as the carboxylate
moiety, is relatively closer to the metal site than 3-Heq. The axial proton resonance of
carbon 3 broadens to a greater extent than that of 3-Heq.
The sialic acid residue of GM1 binds Eu+3 via multiple coordination sites
(Figure 2.7). Free sialic acid binding (as predominantly the β-pyranose form) to metals
has also been reported.2.12 The carboxylate, pyranose ring and glycerol side-chain
oxygens of sialic acid directly participate in coordination. When sialic acid is titrated with
27

2.2 in D2O, the 1H-NMR signals corresponding to the protons on the glycerol side chain
and pyranose ring undergo substantial peak-broadening. The 3Hax proton, on the same
side of the pyranose as the carboxylate moiety, is relatively closer to the metal site than
3-Heq. The axial proton resonance of carbon 3 broadens to a greater extent than that of
3-Heq (Figure 2.11).
Many compounds are present in typical ganglioside extracts (Figure 2.7-2.9).2.13
Major components include free sialic acids, phospholipids, myelins, proline and
glucosamine.

These and many structurally-related compounds do not interfere with

ganglioside detection in neutral buffer solution (Figure 2.7). Interestingly, the
disiaiogangliosides (GD1a and GD1b, Figure 2.9)-2.2 complexes show stronger emission
than the corresponding complex of monosialo GM1-2.2.
Based on these results, we conclude, in agreement with Sillerud et al., that a sialic
acid moiety appended to an oligosaccharide sequence leads to enhanced affinity.
Comparison of the fluorescence spectra of 2.2 in the presence of GM1 with neutral asialo
GM1 as well as several other analytes suggests that proximal oligosaccharide-sialic acid
sequences are important factors leading to signal transduction (Figure 2.7).
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Gangliosides and neutral sugars can also be monitored using the well-known
fluorescent europium(III)-tetracycline (Eu-Tc) complex. The Eu-Tc complex exhibits
efficient ligand to metal energy transfer (LMCT).2.14 This allows for fluorescence
monitoring at the common europium emission wavelength of 615 nm, rather than at the
ligand emission, as in the case of 2.1 or 2.2 (Figure 2.13). The Eu-Tc complex is wellknown to exhibit fluorescence emission enhancement upon complexation via
displacement of bound water.2.14 However, the Eu-Tc complex is not as selective as 2.1
and 2.2. It exhibits fluorescence emission enhancement in the presence of several neutral
sugars and anions.
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Figure 2.13. Fluorescence intensity change of solutions of Eu-Tc complex (5.53 ×
10-6 M) in response to added gangliosides (1.1 × 10-4 M) and sialic acid (1 × 10-3 M) in
0.1 M HEPES buffer solution (pH 7.0). Excitation is at 390 nm, emission at 615 nm.

2.2.3. The Selective Detection of Lysophosphatidic Acid
MeOH solutions containing 2.2 exhibit increased emission in the presence of
commercially available lysophosphatidic acid LPA (oleoyl-L-α-lysophosphatidic acid Na
salt, 5.53 × 10-6 M λex 360 nm λem 403 nm). Solutions containing commercial
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phosphatidic acid PA (3-sn-phosphatidic acid Na salt) exhibit minor fluorescence
changes at 400 nm (Figure 2.14 and 2.15), even at millimolar PA levels.
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Figure 2.14. Fluorescence intensity change of solutions of 2.2 (5.53 × 10-6 M) in
response to added LPA or PA (1.1 × 10-4 M) in MeOH. Emission is at 360 nm, excitation
at 400 nm.

Figure 2.15. Relative fluorescence intensity changes of solutions of 2.1 or 2.2 (5.53 ×
10-6 M) in response to added LPA or PA (1.1 × 10-4 M) in MeOH. Emission is at 360 nm,
excitation at 400 nm. The standard deviation (n=3) of the relative fluorescence intensity
for each analyte ranges from 0.01-0.03.

30

Distinct affinities of LPA and PA for 2.2 can be interpreted in terms of the
magnitude of their corresponding negative charges.2.15 Intramolecular hydrogen bonding
between the phosphate and the 2-sn-OH moieties is observed in the crystal structure of
LPA, and is known to persist at physiological pH (Figure 2.16).2.16 The phosphate
hydroxyl of LPA is thus more prone to ionization as compared to the phosphate proton of
PA. This generates a higher negative charge on the LPA phosphate, facilitating proposed
binding to 2.2 dominated by ionic interactions.
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R: Oleoyl Acid Chain (18:1)
Figure 2.16. Intramolecular hydrogen bonding patterns of LPA and PA explain the lower
pKa of LPA (see reference 2.16).
The free hydroxyl oxygen of LPA may also serve as a cooperative binding site to
the lanthanide. It is known that a second coordinating site, especially one containing a
hard atom such as oxygen or nitrogen, enhances lanthanide affinity (see also Figure 5).2.17
Indeed, we observe significant broadening of the 1H-NMR resonances corresponding to
protons on carbons 1-3 (Figure 2.15) of LPA compared to the other peaks. We propose
that this latter feature, in combination with the relatively higher negative charge of LPA
compared to PA, should allow selective detection of LPA compared to PA, using 2.2.
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Figure 2.19. 1H NMR study of the titration of LPA with 2.2: (a) 1 mg of LPA in 0.75 ml
D2O; (b) after addition of 0.2 equiv 2.2. Significant broadenings of the 1H-NMR
resonances corresponding to protons on carbons 1-3 (3.7 ppm to 4.1 ppm on Figure 2.14)
of LPA are observed.
Ovarian cancer is a global problem. A main reason for the low survival rate of
ovarian cancer is the fact there is no method for early detection. There is evidence that
lysophosphatidic acids (1-acyl-glycerol-3-phosphates), the simplest phospholipids, are
promising markers for the early detection of ovarian cancer.2.18 Current assays for LPA
are unsuitable for routine diagnostic and point-of-care use. LPA is relatively difficult to
detect in nonpolar lipid extracts. LPA is detected selectively by 2.2 via an increase in
fluorescence in MeOH. Figure 2.13 shows that well-known components of phospholipid
extracts

2.19,2.20

do not afford fluorescent emission signals comparable to that of LPA in

solutions of 2.2 in MeOH.
We observe a correlation between fluorescence intensity and LPA concentration
in MeOH extracts of lyophilized human plasma previously spiked with LPA (as well as
LaCl3 to remove neutral interferents, Figure 2.15). LPA is detected in the concentration
range 1.83 × 10-5 M to 9.15 × 10-5 M (Figure 11). Physiological concentrations of LPA in
plasma are ca. < 0.1 to 6.3 μM. Danger levels for ovarian cancer are ca. ≤ 43.1 μM.2.18
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Figure 2.20. Relative fluorescence emission vs. concentration at 437 nm of methanolic
extracts of blood plasma samples containing 2.2 and various concentrations of LPA.
When carried out in triplicate the standard deviation of the relative fluorescence intensity
does not exceed 0.03.

2.3. Conclusion
To date, the lack of receptors that effectively mimic lectin binding is largely due
to the inability to achieve sugar-metal coordination under neutral conditions. The design
of compound 2.1 is inspired by calcium-saccharide interactions found in C-type lectins. It
allows for the successful detection of neutral mono- and oligosaccharides in neutral
buffer solution. Analogs of 2.1 that promote high selectivity for specific sugars in the
visible and near-IR spectral regions will be reported in due course. Our initial studies to
date show that complex 2.2 exhibits enhanced fluorescence emission with anionic lipid
analytes that possess proximal hard atom (oxygen) coordination sites, such as the alpha
hydroxyl of LPA and the oligosaccharide hydroxyls of gangliosides. This is in excellent
accord with prior studies of related systems.2.17 Compound 2.2 can be used to selectively
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detect (i) sialic acid-containing gangliosides in buffer solution and (ii) LPA in MeOH.
These latter results are steps towards developing non-hydrolytic assays for sialic acid and
facilitating the detection of LPA, respectively.

Our initial focus has been on the

selectivity and the signal transduction mechanisms. The complexity of the biomolecules
and the nature of the emission (i.e., ligand emission rather than lanthanide emission)
render the structural study of the tertiary complexes highly challenging. X-ray
crystallographic analysis and further extensive NMR investigations to reveal the precise
nature of the tertiary complexes will be reported in due course.
2.4. Materials and Methods.
2.4.1. Materials and Instrumentation
All chemicals were purchased for Sigma-Aldrich and used without further
purification.

Gangliosides were purchased from Calbiochem. Phospholipids were

purchased from Avanti Polar Lipids. Fluorescence spectra were recorded using a
spectrofluorimeter SPEX Fluorolog-3 equipped with double excitation and emission
monochromators and a 400W Xe lamp.
Bruker DPX-250 or

1

H and

13

C NMR spectra were acquired on a

DPX-300 spectrometer. All δ values were reported in ppm.

Coupling constants are reported in Hz.

Fourier-Transform Infrared Spectra were

acquired on a Tensor 27 Infrared Spectrophotometer (Bruker Optics Inc.). MS were
performed on a Bruker ProFLEX III MALDI-TOF mass spectrometer.
2.4.2. Synthesis of compounds 2.1 and 2.2
The scheme describing the synthesis of 2.1 and 2.2 follows:
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Scheme 2.1. Synthesis of compounds 2.1 and 2.2. 2.1, Ln = LaCl3, 2.2, Ln=EuCl3.
2.4.3. Synthesis of 2.4
To a suspension of K2CO3 (3.76 g, 27.24 mmol) in DMF (60 mL) under N2,
catechol 2.3 (1 g, 9.80 mmol) in DMF (20 mL) and O-acetyl-2-(2-chloro-ethoxy)-ethanol
(2.1 g, 18.16 mmol) in DMF (10 mL) are added. The final mixture is heated overnight at
100 ˚C. K2CO3 is filtered. After the reaction mixture is diluted with EtOAc (60 mL), it is
washed with H2O (4 × 30 mL). The organic phase is dried over Na2SO4 and concentrated
under reduced pressure. The product is obtained as yellow oil (1.5 g, 44.5%). 1H NMR
(250 MHz, DMSO-d6) δ (ppm): 1.99 (6H, s, CH3) 3.69 (8H, m, CH2) 4.09 (8H, m, CH2)
6.92 (4H, m, ArH).

13

C NMR (62.5 MHz, DMSO-d6) δ (ppm): 21.6, 65.0, 69.1, 69.3,

69.8, 115.2, 122.1, 149.2, 171.2.
2.4.4. Synthesis of 2.52.21
2.4 (1.6 g, 4.32 mmol) is dissolved in DCM (50 ml). The solution is cooled on an
ice bath and fuming HNO3 (12 mL) is added. The ice-bath is removed and the solution is
stirred overnight at room temperature. The reaction mixture is poured onto a mixture of
ice and water (80 mL). The organic phase is collected, neutralized with 10% NaHCO3
and washed with H2O. The organic layer is dried over anhydrous Na2SO4. The solvent is
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removed under reduced pressure. The product is chromatographed on silica gel to give
compound 2.5 (1.6 g, 80.5%). 1H NMR (250MHz, DMSO-d6) δ (ppm): 1.97 (6H, s, CH3)
3.68 (2H, t, CH2) 3.80 (2H, t, CH2) 4.10 (2H, t, CH2) 4.33 (2H, t, CH2) 7.79 (2H, s, ArH).
13

C NMR (62.5 MHz, DMSO-d6) δ (ppm): 21.4, 55.7, 64.0, 69.3, 70.4, 110.1, 136.7,

152.0, 171.2.
2.4.5. Synthesis of 2.6
To a solution of 2.5 (0.52 g, 1.13 mmol) in MeOH (30 mL), KOH (0.13 g, 2.26
mmol) is added. The mixture is stirred at room temperature for 4 hours. The reaction
mixture is neutralized with 2N HCl. MeOH is removed under reduced pressure. The
product is extracted with DCM. After washing with H2O, the organic layer is dried over
anhydrous Na2SO4. After removing DCM under reduced pressure, 2.5 is obtained (0.33 g,
76.9%) and is used without further purification in the subsequent steps.
2.4.6. Synthesis of 2.1
Compound 2.6 (0.2 g, 0.53 mmol) is dissolved in MeOH (15 mL). Raney Ni is
added. Hydrogenation is carried out at 50 psi and monitored via H2 consumption. Raney
Ni is removed by filtration through celite. The filtrate containing 2.7 is immediately used
in the next step to prevent any unwanted oxidation. To a refluxing solution of LaCl3
(0.13 g, 0.53 mmol) in 10 mL MeOH, o-vanillin (0.16 g, 1.1 mmol) in 10 mL MeOH and
the solution containing 2.7 are simultaneously added over 20 min. The final solution is
refluxed for 2 h. The reaction mixture is concentrated under reduced pressure and the
residue washed with EtOAc (3x 5 mL). The product is obtained as a dark-red solid
(0.37 g).

13

C-NMR (62.5 MHz, DMSO-d6) δ (ppm): 49.4, 56.5, 56.9, 61.1, 69.7, 69.8,

73.1, 73.3, 113.8, 114.0, 118.4, 120.0, 120.9, 123.4, 149.2, 151.4, 192.8. MALDI-Tof
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(m/z): calcd. C30H34LaN2O10, 721.13; found, 721.48. IR (cm-1) 3206.20, 1614.33,
1439.22, 1209.10, 1036.87.
2.4.7. Synthesis of 2.2
This compound is synthesized as described above for 2.1 except EuCl3 is used
instead of LaCl3. The product is obtained as a dark-red solid (0.35 g).

13

C-NMR (62.5

MHz, DMSO-d6) δ (ppm): 49.4, 56.6, 57.0, 61.1, 69.7, 69.8, 73.1, 73.4, 118.4, 119.3,
120.1, 120.9, 123.4, 147.3, 149.0, 149.3, 151.6, 192.8. MALDI-Tof (m/z): calcd.
C30H34EuN2O10, 735.14; found, 735.34. IR (cm-1) 3104.00, 1638.44, 1444.54, 1214.76,
1018.07.
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Figure 2.21. 1H-NMR Spectrum of 2-(2-chloroethoxy)ethyl acetate in DMSO-d6
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Figure 2.22. 13C-NMR Spectrum of 2-(2-chloroethoxy)ethyl acetate in DMSO-d6
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Figure 2.23. 1H-NMR Spectrum of 2.4 in DMSO-d6
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Figure 2.24. 13C-NMR Spectrum of 2.4 in DMSO-d6
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Figure 2.25. 1H-NMR Spectrum of 2.5 in DMSO-d6
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Figure 2.26. 13C-NMR Spectrum of 2.5 in DMSO-d6
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Figure 2.27. 1H-NMR Spectrum of 2.6 in DMSO-d6
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Figure 2.28. 13C-NMR Spectrum of 2.1 in DMSO-d6.
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Figure 2.29. MALDI TOF Spectrum of 2.1.
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Figure 2.30. FTIR Spectrum of 2.1.
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Figure 2.31.

13

C-NMR Spectrum of 2.2 in DMSO-d6.
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Figure 2.32. MALDI.TOF of Spectrum of 2.2.
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Figure 2.33. FTIR Spectrum of 2.2.
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Figure 2.34. Fluorescence intensity changes of 2.1 (5.53 × 10-6 M) in the presence of
mono- and oligosaccharides (1.1 × 10-3 M) in buffer solution (pH 7.0).

Fluorescence Intensity

8500000

8000000

7500000

7000000

6500000

6000000
0

0.0001 0.0002 0.0003 0.0004 0.0005 0.0006 0.0007
[D-glucose] M

Figure 2.35. Binding isotherm observed upon titration of 2.1 with D-glucose in 0.1 M
HEPES buffer, pH 7.0. The concentration of 2.1 is 6 × 10-6 M. The concentration of
saccharide is increased to 6 × 10-4 M. Excitation is at 360 nm, emission is monitored at
400 nm.
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Figure 2.36. Fluorescence intensity spectra of 2.2 in the presence of various
concentrations of LPA in MeOH.
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Figure 2.37. Fluorescence intensity spectra of 2.2 in the presence of various
concentrations of PA in MeOH.
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Figure 2.38. Fluorescence intensity at 400 nm of solutions containing 2.2 in the presence
of various concentrations of PA and LPA.
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CHAPTER 3

MACROCYCLE-DERIVED FUNCTIONAL XANTHENES AND PROGRESS
TOWARDS CONCURRENT DETECION OF GLUCOSE AND FRUCTOSE*
3.1. Introduction
There has been great progress made towards the design, synthesis and evaluation
of organic dyes functionalized with boronic acids for sugar detection.3.1

There are

relatively few studies, however, addressing the simultaneous detection of common
sugars, such as glucose and fructose, in mixtures.3.1,3.2 It has been known for decades that
boronic acids exhibit relatively high affinity for fructose compared to other saccharides.3.3
More recently several glucose-selective chemosensors have been synthesized.3.1 Nearly
all are based on the key discovery by Shinkai and co-workers that scaffolds containing
appropriately spaced bis-boronic acid moieties may selectively chelate glucose.3.1 Herein
we describe novel methodology which shows promise for the detection of both glucose
and fructose via a combination of UV-Vis and fluorescence spectroscopy.
Previously we reported the facile synthesis and isolation of 3.1 on multi-gram
scale via the acid-catalyzed condensation of resorcinol and 4-formylphenylboronic
acid.3.4 Compound 3.1 is soluble in aqueous polar aprotic solvents such as DMSO. We
observed that colorless DMSO solutions containing 3.1 (Figure 3.1), upon standing or
heating at 90 °C for 1 min, turned pinkish-purple. These color changes were monitored

*Reprinted in part with permission from Journal of Fluorescence, 2004, Volume 14,
pages 609-613; Oleksandr Rusin, Onur Alptürk, Ming He, Jorge O. Escobedo, Shan Jiang,
Fareed Dawan, Kun Lian, Matthew E. McCarroll, Isiah M. Warner, Robert M. Strongin.
“Macrocycle-Derived Functional Xanthenes and Progress Towards Concurrent Detection of
Glucose and Fructose”.
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with UV-Vis spectroscopy via the appearance of new absorptions at 465 nm, 500 nm and
536 nm.3.5
We found that upon heating eleven aqueous DMSO solutions each containing
boronic acid resorcinarene macrocycles and eleven respective saccharides, a different
solution color could be observed by visual inspection corresponding to each sugar.3.5 The
colorimetric responses were rapid, quantifiable and reproducible. More recently, we
applied

similar

methodology

towards

the

colorimetric

detection

of

neutral

oligosaccharides.3.6
Mechanistic investigations, based on extensive spectroscopic, chromatographic
and crystallographic studies, revealed that the color formation in the macrocyclecontaining solutions was due to the formation of ring-opened acyclic oligomers
possessing xanthene chromophores (3.2 in Figure 3.1).3.6

Our studies were greatly

facilitated by the pioneering work of Weinelt and Schneider who had earlier described
the reversible mechanism of resorcinarene macrocycle genesis in homogeneous
solutions.3.7
HO
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OH HO
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Figure 3.1. Ring opening of resorcinarene boronic acid macrocycle 3.1 affords acyclic
oligomers containing xanthene moieties.
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We determined that the sugar-promoted signal transduction arose via the
formation of anionic sugar-boronate esters,3.6 in keeping with the well-known properties
of boronic acid-functionalized dyes.3.1

This was confirmed by

13

C-NMR using

isotopically labeled sugars.3.6 Our results were consistent with the important and useful
NMR-based characterizations of related sugar-aryl boronates performed by Norrild and
co-workers.3.8
3.2. Experimental Section
Reagents, solvents and human blood plasma were purchased from Sigma-Aldrich.
Lyophilized blood plasma (5.0 mL) was reconstituted with H2O (2.0 mL) and
deproteinized by addition of MeCN (3.0 mL). Clear filtrate was used for the glucose
detection experiments.
All spectroscopic data was acquired at room temperature. Colored solutions of 1
were produced via preheating DMSO solutions and cooling to room temperature prior to
adding water or plasma and analytes. UV-Vis data was obtained using a Spectramax Plus
384 spectrophotometer (Molecular Devices). Fluorescence spectra were recorded with a
HR2000 fiber optic spectrometer (Ocean Optics). The excitation wavelength was 470 nm
(Ocean Optics LS-450, blue LED) directed into a fluorescence cuvette via a 600 μm
entrance fiber, and emission gathered by a 1000 μm optical fiber at λmax 579 nm.
Configured for fluorescence, the setup used two mirrored screw plugs positioned at 90°
within the cuvette holder for signal enhancement.
3.3. Results and Discussion.
Selective detection of fructose and the ratiometric monitoring of fructose and
glucose via UV-Vis spectroscopy. We find that fructose promotes a striking solution
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color change in the presence of preheated, colored arylboronic acid resorcinarene 3.1
(from pink-purple) instantly at room temperature. Colorless chemosensor 3.1 (5.2 mM)
is heated at a gentle reflux for 3 min in DMSO (0.9 mL) in air to afford a colored solution
containing 3.1. After cooling to room temperature, fructose (1 equiv) in 0.1 mL H2O is
added. A color change from pink-purple to orange-yellow is observed. Glucose, sucrose,
maltose, lactose, xylose, and glucose, 3 equiv each, exhibit no color change within 2 h at
room temperature (Figure 3.2).

Figure 3.2. A selective color change promoted by fructose is observed at room
temperature upon addition to a colored solution containing 3.1.

The color change is monitored by observing the ratiometric absorbance intensity
decrease at 536 nm and increase at 464 nm (Figure 3.3). The absorbance changes exhibit
a linear dependence with fructose concentration (R = 0.9079 and 0.9419 at each of the
two wavelengths, respectively). The ratio of glucose to fructose in blood plasma is ca.
100:1. Addition of 1 equivalent of fructose to a colored solution containing 3.1 at room
temperature results in an 8.6 % increase in the absorbance at 464 nm. Addition of 100
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equivalents of glucose to the fructose/3.1 solution results in no detectable change in the
fructose/3.1 absorbance at 464 nm. Addition of a second equivalent of fructose to this
latter solution results in a readily observable absorbance increase of 3.3 %.
At 536 nm, the absorbance of solutions of 3.1 is lowered by 20 % upon addition
of 1 equiv fructose. Subsequent addition of 100 equivalents of glucose lowers the
absorbance further by 12 %. Addition of another equivalent of fructose again lowers the
absorbance by 24 % (Figure 3.3).
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Figure. 3.3. Upper: Addition of fructose to a preheated (3.0 min at reflux) solution of
3.1 (5.2 x 10-3 M) in DMSO at room temperature affords concentration-dependent
absorbance changes at 464 nm and 536 nm. Lower: UV-Vis spectra of a 9:1
DMSO:H2O solution containing 3.1 (5.2 x 10-3 M) pre-heated (1.5 min at reflux) (i)
alone, (ii) upon addition of 1 equiv fructose at room temperature which produces an
absorbance increase at 464 nm and a corresponding decrease at 536 nm, (iii) upon
addition of 100 equiv glucose which produces no absorbance change at 464 nm but a
decrease at 536 nm and (iv) upon addition of a second equivalent of fructose which
affords a further absorbance increase at 464 nm and decrease at 536 nm.
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This result indicates the potential feasibility of determining fructose, in the
presence of excess of glucose, by monitoring fructose concentrations at 464 nm, where an
absorbance change is not produced in response to glucose. In addition, one should be
able to concurrently determine the glucose present in a sample via analysis of the ratio of
the absorbance at 536 nm (at which wavelength both glucose and fructose promote signal
changes) to the absorbance at 464 nm, for instance, after the fructose concentration is
determined at 464 nm.
The selectivity for fructose appears consistent with our previous binding constant
studies of neutral sugars.3.6 Additionally, we determined that anionic fructose-boronate
formation lowers the pKa of the colored xanthenes (3.2), resulting in absorbance changes.
3.6

It is well-known that xanthene dyes show an increase in absorbance at their shorter

visible wavelength and a decrease in absorbance at their longer visible wavelength in
response to a lowering of solution pH. Thus, we can ascribe the ratiometric responses
observed at 464 nm and 536 nm in the current studies as due, in large part, to a lowering
of xanthene pKa upon sugar binding.
The UV-Vis studies described above would require higher concentrations of
sugars than typically found in most naturally-occurring biological samples in order to
generate useful signals. We are investigating the synthesis and study of new functional
xanthene dyes with enhanced sensitivity in order to avoid concentration steps in sample
monitoring. Since the xanthenes (3.2) are present in colored solutions only at micromolar
levels, 3.6 their synthesis and/or isolation as discreet compounds should afford materials
with higher colorimetric sensitivity, since a significant amount of sugar binds to excess
colorless boronic acid 3.1. We meantime find, however, that colored solutions containing
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3.1 show promise for monitoring glucose levels in the range of physiological levels via
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Figure 3.4. Upper: Fluorescence emission changes produced upon addition of Dglucose to a colored solution (DMSO:H2O 9:1) containing 3.1 (5.0 x 10-3 M) at room
temperature. The glucose concentration was increased from 0 to 7.4 x 10-4 M. Lower:
Fluorescence emission changes produced upon addition of D-fructose to a colored
solution (DMSO:H2O 9:1) containing 3.1 (5.0 x 10-3 M) at room temperature. The
fructose concentration was increased from 0 to 1.8 x 10-3 M.
Enhanced glucose selectivity via fluorescence detection in the range of
physiological concentrations and in human blood plasma. The fluorescence emission
spectra of colored solutions containing 3.1 and added glucose or fructose are shown in
Figure 3.4. As the sugar concentration is increased we observe concomitant emission
increases promoted by fructose and glucose. The significant signaling generated by
glucose is in contrast to the UV-Vis studies (vide supra) in which relatively much weaker
absorbance responses were promoted by glucose as compared to fructose.

62

The normal level of D-fructose in human blood plasma is ca. 50 μM.
Fluorescence emission spectra of colored solutions containing 3.1 and added fructose,
obtained over the fructose concentration range of 20 μM to 100 μM, exhibit no detectable
fructose-promoted emission. Healthy levels of D-glucose are ca. 5 mM. The emission
spectra of glucose (5.5 x 10–3 M) and 3.1 (1.0 x 10–3 M) in DMSO:H2O, 9:1, as well as in
a 9:1 DMSO:plasma solution, are shown in Figure 3.5. Emission increases due to the
presence of glucose are observed in both cases. A dependence of fluorescence emission

Intensity (a.u.)

intensity on increased glucose levels in plasma is observed (Figure 3.5).
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Figure. 3.5. Upper: Fluorescence emission spectra produced by (i) a preheated (3 min
at reflux) colored solution (DMSO:H2O 9:1) containing 3.1 (5.0 x 10-3 M) at room
temperature, (ii) the same conditions but in the presence of 20 μM D-fructose, added at
room temperature, which affords no observable change in emission, (iii) the same
conditions as (i) but with added D-glucose (5.3 μM ) which promotes an emission
increase and (iv) same conditions as (iii) but in deproteinized human blood plasma
instead of H2O, which exhibits an emission increase in response to added glucose.
Lower: Concentration-dependent emission changes produced via room temperature
additions of D-glucose to a 9:1 DMSO:plasma solution containing 1.
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The results of the fluorescence studies show that the boronic acid-functionalized
xanthenes (3.2) may promote the detection of glucose in blood plasma with negligible
interference from fructose.

New UV-Vis and near-IR absorbing congeners of 3.2,

possessing functionality for greater potential glucose signaling ability, are currently being
designed in our lab to address potential fluorescence interference issues in blood plasma.
The enhanced fluorescence emission promoted by glucose, as compared to its
relatively weaker UV-Vis responses (e.g., relative to fructose), may be attributed to
chelation by neighboring boronic acids of 3.2. It is well-known that glucose can be
chelated by bis-boronic acids. This results in chemosensor scaffold rigidification effects,
which

have

been

previously

demonstrated

to

afford

fluorescence

emission

enhancement.1,9 An excess of boronic acid binding sites relative to glucose should
promote chelation.

The large excess of non-absorbing 3.1 compared to responsive

fluorophores (3.2) should thus facilitate glucose-promoted emission by competing for
glucose binding to 3.2.
3.4. Conclusion
We have presented evidence that oligomeric xanthene dye-functionalized boronic
acids, which form in situ from tetraaryl boronic acid resorcinarene macrocycles, show
promise for the selective detection of glucose and fructose. The fluorescence studies
indicate that selectivity for glucose over fructose at physiological levels in plasma may be
achieved. Via UV-Vis spectroscopy, we observe high fructose selectivity. Additionally,
ratiometry may also be used to simultaneously measure fructose and glucose levels, at
proportionally higher concentrations. The mechanistic insights gained from these results
will aid us in designing improved xanthene-derived chemosensors with tuneable
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properties. The synthesis of water soluble and surface-bound congeners of the molecules
described herein is also in progress.
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CHAPTER 4
ORGONAMETALLIC COMPLEXES AS THERAPEUTIC AGENTS

4.1. Introduction
This chapter describes the synthesis and applications of synthetic organometallic
complexes herein called metallosalophenes (MSPs).
analogs.

Included are metal-chelating

The animal studies described herein were performed at Brown University

Medical School under the direction of Dr. Laurent Brard.
MSPs are currently employed in the protection of tissues and/or cell types during
cancer chemotherapy4.1, as de-novo drugs and or analogs possessing such therapeutic
applications as anti-neoplastic, anti-angiogenic and anticancer activity4.2. More
importantly, they function as free radical scavengers4.3 in the case of the some other
diseases such as Alzheimer’s4.4.
It has now been discovered that a number of MSPs display anticancer activity.
This has been demonstrated in vitro in various cultured solid tumor cancer cells such as
neuroblastoma, breast, ovarian, prostate, pancreatic, vulvar, and liver and in other nonsolid human tumors too. Furthermore, MSP anticancer activity is present in vivo.
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Figure 4.1. The structures of metallosalophenes
66

OCH3
O
H2O
Fe
Cl
N
O
OCH3
N

N

N

4.4

N

N

4.1

O

OCH3
O
H2O
Fe
Cl
N
O
OCH3

OCH3

OCH3

S

4.6

The preparation of the salophene-based metal complexes involve a condensation
reaction of a substituted salicylaldehyde and a substituted diamine.4.5 In general, the
quantities of these compounds are reacted in a 2:1 molar ratio in absolute ethanol. The
solutions are refluxed for 1 h. The salophene ligand is either precipitated in analytically
pure form by the addition of water, or the metal complex is generated directly by addition
of the corresponding metal as its acetate, halide, or triflate salt.
Another method of preparing the complexes is as follows: the starting diamine is
R,R- or S,S-1,2-diamino-1,2-diphenylethane and the starting salicylaldehyde is 3-tertbutylsalicylaldehyde. A solution of 2.0 mmol of 3-tert-butylsalicylaldehyde in 3 ml of
absolute ethanol is added dropwise to a solution of 1.0 mmol of (R,R)-1,2-diamino-1,2diphenylethane in 5 ml of ethanol. The reaction mixture is heated to reflux for 1 h and
then 1.0 mmol of Mn(OAc)2. 4 H2O is added in one portion to the hot (60° C.) solution.
The color of the solution immediately turns from yellow to brown upon addition. It is
refluxed for an additional 30 min and then cooled to room temperature. A solution of
10% NaCl (5 ml) is then added dropwise and the mixture stirred for 0.5 h. The solvents
are then removed in vacuo and the residue is triturated with 50 ml of CH2Cl2 and 50 ml of
H2O. The organic layer is separated and the brown solution is washed with saturated
NaCl. Separation of the organic phase and removal of solvent resulted in a crude
material which can be recrystallized from C6H6/C6H14 to give a (R,R)-salophene-Mn
complex.
Salophenes 4.3 and 4.6 are synthesized as per the scheme described below
(Scheme 4.1. and Scheme 4.2).
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Scheme. 4.1. The synthesis of 4.3.
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4.2. Results and Discussion
4.2.1. Iron-Salen Complex Inhibits Proliferation of Epithelial Ovarian Cancer Cells
Given the exciting activity of iron-salen on platinum-resistant SKOV-3 epithelial
ovarian cancer cells, we re-assessed viability via the MTS assay using a narrow dose
range (0-5 μM). These additional experiments have re-confirmed the previous
conclusions (IC50 = 630 nM, Figure 4.2) and added additional insight regarding the
potency of this iron-salen complex.
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Figure 4.2. Iron-salen significantly inhibits the viability of SKOV-3 ovarian cancer cells.
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4.2.2. Acute Toxicity Studies
Iron-salen was administered orally and intra-peritoneally to two groups of 7
animals and acute toxicity was evaluated by the up-and-down method. The estimated
LD50 was >2000 mg/kg body weight (PO) and > 5.5mg/kg, body weight (IP) (Figure
4.9).
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4.2.3. Caspase Activation in vivo
The possible role of caspase-3 in iron-salen induced apoptosis in vivo was
evaluated by Western blotting wherein the full-length and activated from of caspase-3 are
probed by the use of specific antibodies. Following treatment, tumor tissue was harvested
and this tissue was sonicated for 5 minutes. After this material re-suspended in lysis
buffer, it is separated on 12% SDS PAGE. Subsequently, it is blotted on to PVDF
membrane and treated with antibodies specific for monitoring both pro- and activated
caspase-3 (Figure 4.4). Treatment of 344 Fischer rats injected NUTU-19 ovarian cancer
cells by iron-salen resulted in cleavage of pro-caspase-3 in a dose-dependent manner, as
evidenced by the appearance of 19 and 17 kDa intermediates. PARP-1 cleavage was
measured by employing antibodies specific to cleaved PARP-1. Treatment of 344 Fischer
rats injected NUTU-19 ovarian cancer cells resulted in PARP-1 cleavage in a dosedependent fashion, as shown by the increase of the 85 kDa inactive intermediate band.
Increased PARP-1 cleavage coincided with increased caspase-3 activation. The caspase-3
and PARP-1 results suggest that iron-salen affects ovarian cancer cells in a similar
fashion both in vitro and in vivo.
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Figure 4.4. Caspase-3 activation and PARP-1 inactivation by Iron-Salen
4.2.4. Preliminary Therapeutic Trial
In this preliminary trial, twenty rats, divided into two treatment groups of five
animals each (0.5 mg/kg and 1.0 mg/kg) and one control group (12 animals) were used.
The rat ovarian cancer model has been described elsewhere.4.6 NUTU-19 cells were
cultured to 80% confluence, harvested, counted for cell number and viability, and
injected intra-peritoneal (IP). Iron-salen was applied to two treatment groups in the form
of daily IP injections (the stock solution of iron-salen in DMSO/water (20/80 v/v)
mixture were diluted 100-fold prior to injection) and vehicle (DMSO/water 20/80 v/v)
was injected to the untreated control group. Two different concentrations of iron-salen
are determined based on previous in vitro work and acute toxicity results.
The treatment of experimental animals began in week 3 to mimic the conditions
following cytoreductive surgery. According to this model, 100% of animals develop
disease after three weeks and are euthanized secondary to overwhelming tumor burden by
8-12 weeks (post-injection). Duration of treatment was 12 days and was based on tumor
burden in the control animals. Animals were monitored for any discomfort and pain per
IACUC protocols. All twenty animals were euthanized at week 5 and tumor tissue was
harvested. While control animals showed a constantly elevated amount of hemorrhagic
ascites, those treated with the iron-salen treated displayed substantially less hemorrhagic
ascites volume (Figure 4.5). More importantly, decrease in ascitic volume appeared to be
dose-dependent. The difference was especially substantial in the 1mg/Kg treatment
group.
Parallel results were afforded with omental weight between control and treatment
groups. As previously depicted, it was found to be consistently higher in control animal
than in treatment groups. Furthermore, 7 (70%) animals afforded response to treatment
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with iron salen during this preliminary treatment trial. As 40% of treated animals
displayed a complete response (Figure 4.6 and 4.7), 30% had partial response.
Consequently, these preliminary in vivo experiments have provided a firm
evidence that iron-salen is a potent anti-ovarian cancer drug with high potential in the
treatment of this devastating disease.
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Figure 4.5. (Top) Effect of Iron-Salen on Tumor Burden: Weight of Omentum (bottom)
Effect of Iron-Salen on Hemorrhagic ascites.
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Figure 4.6. (Left) Photograph of diaphragm in treated rat (1 mg/Kg). Arrow: Normal diaphragm, (right) Photograph of diaphragm in
control rat. Arrows represent tumor nodules
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Figure 4.7. (Left) Photograph of omentum in treated rat (1 mg/Kg). A = Stomach, B = Omentum), (right) Photograph of omentum in
control rat. Arrows represent tumor nodules.
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4.3. Experimental Section.
4.3.1. Synthesis of 4.8
To a suspension of o-vanillin (1.52 g, 9.99 mmol) in of anhydrous ethanol
(15 ml), 1,2-diaminobenzene (0.54 g, 4.99 mmol) is added. Upon reflux for 2 hours, an
orange precipitate is afforded. The final compound 4.8 is isolated via suction and washed
with cold ethanol (1.5 g, 80.2%).4.7 1H-NMR (300 MHz, DMSO-d6) δ (ppm): 3.82
(s, 6H), 6.9 (t, J = 7.87 Hz, 2H), 7.14 (d, J = 7.34 Hz, 2H), 7.27 (d, J = 7.65 Hz, 2H),
7.41-7.48 (m, 4H), 8.93 (s, 2H).13C-NMR (62.5 MHz, DMSO-d6) δ (ppm): 57.6, 117.3,
120.5, 121.3, 121.8, 125.8, 125.8, 129.8, 144.1, 149.9, 152.6, 166.3.
4.8.2. Synthesis of 4.3
To a suspension of 4.8 (0.4 g, 1.06 mmol) in anhydrous ethanol (15 ml),
FeCl3.6H2O (0.286 g, 1.06) is added. Upon reflux for 1 hour, a grey-black precipitate is
afforded.4.8 The final compound 4.3 is isolated via suction and washed with cold ethanol
(0.11 g, 21.5%).

4.8.3. Synthesis of 4.6
The compound 4.6 is prepared in situ upon from the condensation reaction of
3,4-diaminothiophene 4.9 and o-vanillin in the presence of FeCl3.6H2O. To a solution of
o-vanillin

(057

g,

3.74

mmol)

in

of

anhydrous

ethanol

(7

ml),

3,4-diaminothiophene.2HCl (0.35 g, 1.87 mmol) and FeCl3.6H2O (0.5 g, 1.87 mmol) are
added. Upon reflux for 1 hour, a dark-blue precipitate is afforded. The final compound
4.6 is isolated via suction and washed with cold ethanol (0.52 g, 56.7%).
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Figure 4.8. 1H-NMR of 4.8
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Figure 4.9. 13C-NMR of 4.8.
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Figure 4.10. FTIR of 4.8.
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Figure 4.11. FTIR of 4.3.

78

Figure 4.12. FTIR of 4.6.

79

4.3.

For an extensive review, see: Riley, D. P. Chem. Rev., 1999, 99, 2573

4.4.

Henke, S. L. Expert. Opin. Ther. Pat. 1999, 9, 169.

4.5.

Hennessy, E. J.; Buchwald, S. L. J. Org. Chem., 2005, 70, 7371.

4.6.

Robison, K.; Steinhoff, M. M.; Granai, C. O.; Brard, L.; Gajewski, W.; Moore,
R. G. Gynecol. Oncol. 2006, 101, 24.

4.7.

Caifeng, B.; Yuhua, F.; Guoxin, S.; Gengxiu, Z.; Guangyou. Z. Syn. React. Inorg.
Met. 2001, 31, 219.

4.8.

Zanello, P.; Cini, R.; Cinquantini, A. Polyhedron, 1985, 4, 1383.

80

APPENDIX A. LETTER OF PERMISSION FROM PNAS
PNAS Author Rights and Permission FAQs
1.

If I transfer copyright to PNAS, what rights do I have?

As a PNAS author, you and your employing institution or company retain extensive rights
for use of your materials and intellectual property. You retain these rights and permissions without
having to obtain explicit permission from PNAS, provided that you cite the original source and
copyright notice:
•
•
•
•

•
•
•
•

•

The right to post a PDF of your article on your web site or that of your employer's
institution (provided that the institution is nonprofit).
The right to make electronic or hard copies of articles for your personal use, including
classroom use, or for the personal use of colleagues, provided those copies are not for
sale and are not distributed in a systematic way outside of your employing institution.
The right to post and update a preprint version of your article on a public electronic server
such as the World Wide Web. See the information on electronic preprints below.
The right to permit others to use your original figures or tables published in PNAS for
noncommercial and educational use (i.e., in a review article, in a book that is not for sale),
provided that the original source and copyright notice are cited. Third parties need not
ask PNAS for permission to use figures and tables for such use
The right, after publication in PNAS, to use all or part of your article in a printed
compilation of your own works, such as collected writings or lecture notes.
If your article is a "work for hire" made within the scope of your employment, your
employer may use all or part of the information in your article for intracompany use.
The right to include your article in your thesis or dissertation.
The right to present all or part of your paper at a meeting or conference, including ones
that are webcast, and to give copies of your paper to meeting attendees before or after
publication in PNAS. For interactions with the media prior to publication, see the PNAS
Policy on Media Coverage.
The right to publish a new or extended version of your paper provided that it is sufficiently
different to be considered a new work.
o The right to expand your article into book-length form for publication.
o The right to reuse your original figures and tables in your future works.
o Patent and trademark rights or rights to any process or procedure described in
your article
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APPENDIX B. LETTER OF PERMISSION FROM SPRINGER
Dear Onur Alpturk,
This letter is to inform you that Springer gives permission to Onur
Alpturk, 2nd author of article entitled "Macrocycle-Derived Functional
Xanthenes and Progress Towards Concurrent Detection of Glucose and
Fructose" published in Journal of Fluorescence (J. Fluoresc., 2004,
14(5), 609-613 to use the article mentioned in his thesis for
educational purposes as stated in your request dated April 5th, 2007.
The fee associated with this permission is waived based on the fact
that
the article will only be used in thesis for educational reasons; and
will not be reproduced. If the article is reproduced; please contact me
directly at 212-620-8495 for additional permission and at which point a
fee will be imposed.
All the best,
Evelisa Rosario
Springer
Corporate Reprint Sales Assistant
233 Spring Street | 7th floor | New York
NY 10013 | USA
Office +1 (212) 620-8495
New Fax
+1 (212) 620-8442
evelisa.rosario@springer.com
www.springer.com

-----Original Message----From: Onur Alpturk [mailto:oalptu1@lsu.edu]
Sent: Thursday, April 05, 2007 4:40 PM
To: Rosario, Evelisa, Springer US
Subject: Request for Permission
Importance: High
To whom this may concern,
My name is Onur Alpturk and I am 2nd author of the paper titled as
"Macrocycle-Derived Functional Xanthenes and Progress Towards
Concurrent
Detection of Glucose and Fructose" published in Journal of Fluorescence
(J. Fluoresc., 2004, 14(5), 609-613). I would like to ask for
permission
to include this paper into my thesis.
Best Regards,
Onur Alpturk

82

VITA

Onur Alptürk was born in Ankara, Turkey, on April, 17th of 1975. After
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Louisiana State University (LSU) in Baton Rouge, Louisiana. Under the guidance of Prof.
Robert M. Strongin, he has developed the synthesis of novel lanthanide based
chemosensors for the quantification of carbohydrates and certain cancer biomarkers. In
collaboration with Prof. Laurent Brard from Brown University, Medical School, he
worked on the synthesis and applications of metallosalophenes for treatment of the
ovarian cancer. His research gathered him LSU Research Award in chemistry. The
degree of Doctor of Philosophy will be awarded to him at the May 2007 commencement.

83

